Protective Mechanisms of Liquid Formulations for Gastro-Oesophageal Reflux Disease in a Human Reconstructed Oesophageal Epithelium Model

被引:4
作者
Ceriotti, Laura [1 ]
Buratti, Paolo [1 ]
Corazziari, Enrico Stefano [2 ]
Meloni, Marisa [1 ]
机构
[1] VitroScreen Srl, In Vitro Innovat Ctr, Via Mose Bianchi 103, I-20149 Milan, Italy
[2] IRCCS Humanitas Res Hosp, Dept Gastroenterol, Milan, Italy
关键词
gastro-oesophageal reflux disease; film-forming properties; caffeine permeation; epithelial permeability; epithelial protection; Lucifer yellow assay; BARRIER FUNCTION; HYALURONIC-ACID; MANAGEMENT; PENETRATION; EXPRESSION; SKIN;
D O I
10.2147/MDER.S363616
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Purpose: A novel experimental design based on a human-reconstructed oesophageal epithelium (HO2E) model has been applied to quantitively assess the properties of a set of liquid formulations, Device A (Gerdoff (R) Protection), Device B (Esoxx (R) One), and Device C (Marial (R) gel) developed to form a temporary physical barrier on the oesophageal epithelium and modify epithelial permeability so to protect the oesophageal mucosa from refluxate components. Methods: The formulations were applied to a prewetted HO2E model for 15 min. Then, a 0.5% caffeine solution was applied, and its penetration kinetics was assessed at 1 h and 2 h in acidic environments (pH= 3.3) to mirror exposure of the oesophageal mucosa to acidic reflux in GORD patients. Caffeine permeated into the basolateral compartment (evaluated by HPLC-UV) and Lucifer yellow (LY) permeability were quantified 15 min after application of the caffeine in acidic environments. Results: At the 15 min timepoint, Device A reduced caffeine permeation by 77.2% and LY flux by 30.4% compared to the untreated control and with a faster mode of action than that of the other liquid formulations. Transepithelial caffeine flux was reduced, albeit with different timing and efficiency, by all three compounds up to the end of the 2 hour experiment. At 1 h, Device A reduced the caffeine flux by 79.2%; Device B, by 67.2%; and Device C, by 37%. Conclusion: These results confirm the ability of the medical devices tested to interact with the oesophageal epithelium and create a temporary physical protective film for up to 2 hours after their application. The results underline differences in the mechanism of action of the three medical devices, with Device A performing faster than the other formulations. The overall results support the relevance of the reconstructed mucosal model to investigate oesophageal epithelium-product interactions and precisely differentiate liquid formulation performance.
引用
收藏
页码:143 / 152
页数:10
相关论文
共 32 条
[1]   The Phenion® Full-Thickness Skin Model for Percutaneous Absorption Testing [J].
Ackermann, K. ;
Borgia, S. Lombardi ;
Korting, H. C. ;
Mewes, K. R. ;
Schaefer-Korting, M. .
SKIN PHARMACOLOGY AND PHYSIOLOGY, 2010, 23 (02) :105-112
[2]   Protective and regenerative effects of a novel medical device against esophageal mucosal damage using in vitro and ex vivo models [J].
Agostinis, Chiara ;
Bossi, Fleur ;
Mangogna, Alessandro ;
Balduit, Andrea ;
Pacor, Micol ;
Giacomello, Emiliana ;
Belmonte, Beatrice ;
Greco, Daniele ;
Rodolico, Vito ;
Voinovich, Dario ;
De Seta, Francesco ;
Ricci, Giuseppe ;
Bulla, Roberta .
BIOMEDICINE & PHARMACOTHERAPY, 2020, 131
[3]   Development of an In Vitro System to Study the Interactions of Aerosolized Drugs with Pulmonary Mucus [J].
Alqahtani, Safar ;
Roberts, Clive J. ;
Stolnik, Snjezana ;
Bosquillon, Cynthia .
PHARMACEUTICS, 2020, 12 (02)
[4]  
[Anonymous], 2016, EMACHMPCVMPJEG3RS450
[5]   Altered localization and expression of tight-junction proteins in a rat model with chronic acid reflux esophagitis [J].
Asaoka, D ;
Miwa, H ;
Hirai, S ;
Ohkawa, A ;
Kurosawa, A ;
Kawabe, M ;
Hojo, M ;
Nagahara, A ;
Minoo, T ;
Ohkura, R ;
Ohkusa, T ;
Sato, N .
JOURNAL OF GASTROENTEROLOGY, 2005, 40 (08) :781-790
[6]   Esophageal barrier function and tight junction expression in healthy subjects and patients with gastroesophageal reflux disease: functionality of esophageal mucosa exposed to bile salt and trypsin in vitro [J].
Bjorkman, Eleonora Victoria Charlotta ;
Edebo, Anders ;
Oltean, Mihai ;
Casselbrant, Anna .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2013, 48 (10) :1118-1126
[7]   Symptomatic response to GERDOFF® in patients with gastro-esophageal reflux disease and poor response to alginates: an exploratory, post-market, open-label study [J].
Boarino, Valentina ;
Raguzzi, Ivana ;
Marocchi, Margherita ;
Merighi, Alberto .
TURKISH JOURNAL OF GASTROENTEROLOGY, 2020, 31 (06) :466-+
[8]   Symptomatic reflux disease: the present, the past and the future [J].
Boeckxstaens, Guy ;
El-Serag, Hashem B. ;
Smout, Andre J. P. M. ;
Kahrilas, Peter J. .
GUT, 2014, 63 (07) :1185-1193
[9]   In vitro method to evaluate the barrier properties of medical devices for cutaneous use [J].
Casiraghi, Antonella ;
Ranzini, Francesco ;
Musazzi, Umberto M. ;
Franze, Silvia ;
Meloni, Marisa ;
Minghetti, Paola .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2017, 90 :42-50
[10]   Further development of an in vitro model for studying the penetration of chemicals through compromised skin [J].
Davies, Diane J. ;
Heylings, Jon R. ;
Gayes, Heather ;
McCarthy, Timothy J. ;
Mack, M. Catherine .
TOXICOLOGY IN VITRO, 2017, 38 :101-107